US regulators have decided to apply the Pfizer anti-covid-19 vaccine to children between the ages of 12 and 15 years of age so that they are safe on their way back to school and their normal activities can begin.
Washington: US regulators have decided to apply Pfizer’s anti-Covid-19 vaccine to children between the ages of 12 and 15 years so that they are safe on their way back to school and can begin their normal activities. Vaccination of children can be started from Thursday after the Federal Vaccine Advisory Committee recommends applying two doses of the vaccine to 12- to 15-year-olds. It is likely to be announced on Wednesday.
Many anti-Covid-19 vaccines are allowed to be grown in the world. However, the Pfizer vaccine is being administered to 16-year-old adolescents in many countries. Recently, Canada started vaccinating children 12 years and older, becoming the first country to do so. “This is an important moment in the direction of dealing with the global pandemic Covid-19,” Dr Bibel Gruber, Senior Vice President and Pediatrician of Pfizer, told AP. “Food and Drug Administration 12 to 15 years The vaccine was announced to be safe for teens after testing on more than two thousand children.
EU agrees to buy Pfizer’s potential 1.8 billion doses
The European Union (EU) has extended its support to Pfizer-Biotech and its Covid-19 vaccine technology by 2023, agreeing on a huge contract extension for a potential 1.8 billion dose. European Union Commission Chairperson Ursula von der Leyen tweeted that her office has “just approved a contract for 90 million guaranteed doses”. The new contract has the backing of EU member states. This will not only give the right to produce vaccines but will also ensure that all the necessary ingredients are mobilized from the European Union. The European Union currently has 2.3 billion doses of half a dozen companies.
The commission chair tweeted, “Other contracts and other vaccine technologies will also be considered.” Pfizer-Biotech initially had a 600 million dose contract with the European Union. Saturday’s announcement underscores that the European Union has expressed confidence in Pfizer-Biotech’s technology and that the technology is different from the technology of the Oxford AstraZeneca vaccine. This major expansion in the contract has been announced at a time when the European Union is finding the required buster doses and modalities to deal with the challenge of new mutated varieties in particular. At the same time, he is also in favour of conducting a vaccination campaign for children and adolescents.
Von der Leyen stated that, unlike AstraZeneca, Pfizer Biotech is a trusted partner that fulfils its promise in terms of supply. Last week, the European Union initiated legal action against AstraZeneca for failing to sign a contract. Although the Astrazenka vaccine has been at the centre of Europe’s vaccination campaign and has been the pivot of the global strategy of providing vaccines to poor countries, Europeans are angered by its slow supply.